OccamzRazor, a New York-based first curative therapies for Parkinson’s, discovered with machine learning, closed $6.1 million in funding to launch their AI-enabled discovery pipeline and advance preclinical development in Parkinson's.
This round was led by Jeff Dean, one of the top AI researchers in modern machine learning today. Other investors include Lauder Partners, re.Mind Capital, and Valor Equity Partners.
Company: Razor, Inc.
Funding Month: March 2022
Lead Investors: Jeff Dean
Additional Investors: Lauder Partners, re.Mind Capital, and Valor Equity Partners
Company Website: https://www.occamzrazor.com/
Software Category: AI-enabled discovery pipeline and advance preclinical development
About the Company: OccamzRazor is a digital biotech company that focuses on the discovery and development of modality agnostic treatments for complex diseases of brain aging, founded to help patients with brain-aging disorders where there is a lack of treatment options that halt or reverse the disease. By combining graph machine learning (RazorBrain™), graph prediction (RazorLink™), and natural language processing (RazorPanorama™), OccamzRazor generates testable, data-driven hypotheses that increase success rates and reduce costs in neurodegenerative drug development. The company is headquartered at Johnson & Johnson's innovation hub J-LABS in New York City.